Wall Street brokerages forecast that Urogen Pharma (NASDAQ:URGN) will report earnings of ($0.05) per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Urogen Pharma’s earnings. The lowest EPS estimate is ($0.46) and the highest is $0.10. The business is scheduled to announce its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Urogen Pharma will report full-year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($2.74) to ($1.76). For the next year, analysts expect that the business will post earnings of ($2.89) per share, with EPS estimates ranging from ($4.19) to ($1.76). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Urogen Pharma.

URGN has been the subject of a number of research analyst reports. Cowen and Company initiated coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating for the company. Jefferies Group LLC started coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective for the company. Oppenheimer Holdings, Inc. started coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $32.00 price objective for the company. Raymond James Financial, Inc. started coverage on shares of Urogen Pharma in a research note on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research raised shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.00.

Urogen Pharma (NASDAQ URGN) opened at 32.49 on Friday. The firm’s market capitalization is $422.66 million. Urogen Pharma has a one year low of $13.01 and a one year high of $32.95. The stock’s 50 day moving average price is $20.93 and its 200 day moving average price is $18.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/urogen-pharma-urgn-expected-to-post-earnings-of-0-05-per-share.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Alps Advisors Inc. acquired a new stake in Urogen Pharma during the second quarter worth approximately $195,000. LLBH Private Wealth Management LLC acquired a new stake in Urogen Pharma during the second quarter worth approximately $695,000. Spark Investment Management LLC acquired a new stake in Urogen Pharma during the second quarter worth approximately $856,000. Menora Mivtachim Holdings LTD. acquired a new stake in Urogen Pharma during the second quarter worth approximately $2,331,000. Finally, Wildcat Capital Management LLC acquired a new stake in Urogen Pharma during the second quarter worth approximately $2,439,000. Hedge funds and other institutional investors own 36.06% of the company’s stock.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.